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Identify whether participants with lower education are less likely to report taking statins for primary 
cardiovascular prevention than those with higher education, but an equivalent increase in underlying 
cardiovascular risk. 
Methods:  
Using data from a large prospective cohort study, UK Biobank, we calculated a QRISK3 cardiovascular 
risk score for 472 097 eligible participants with complete data on self-reported educational attainment 
and statin use (55% female; mean age, 56). We used logistic regression to explore the association 
between i) QRISK3 score and ii) educational attainment on self-report statin use. We then stratified the 
association between QRISK3 score and statin use, by educational attainment to test for interactions.  
Results: 
There was evidence of an interaction between QRISK3 score and educational attainment. Per unit 
increase in QRISK3 score, more educated individuals were more likely to report taking statins. In women 
with ≤7 years of schooling, a one unit increase in QRISK3 score was associated with a 7% higher odds of 
statin use (odds ratio (OR)(1.07, 95% CI 1.07, 1.07). In women with ≥20 years of schooling, a one unit 
increase in QRISK3 score was associated with an 14% higher odds of statin use (OR 1.14, 95% CI 1.14, 
1.15). Comparable ORs in men were 1.04 (95% CI 1.04, 1.05) for ≤7 years of schooling and 1.08 (95% CI 




Per unit increase in QRISK3 score, individuals with lower educational attainment were less likely to 





What is already known on this topic? 
Despite reductions in the rates of cardiovascular disease in high income countries, individuals who are 
the most socioeconomically deprived remain at the highest risk of disease. Although intermediate 
lifestyle and behavioural risk factors explain some of this, much of the effect remains unexplained. 
What does this study add? 
Per unit increase in QRISK3 score, a measure of clinical need, the likelihood of statin use increased more 
in individuals with high educational attainment compared with individuals with lower educational 
attainment .These results were similar when using UK Biobank to derive QRISK3 scores and when using 
QRISK scores recorded in primary care records, and when using self-reported statin prescription data or 
prescription data from primary care records. 
How might this impact clinical practice? 
The mechanisms leading to these differences are unknown, but both health seeking behaviours and 
clinical factors may contribute. Clinicians and policy makers should consider how they can improve 
uptake of preventative health checks to carry out risk cardiovascular risk assessments, whilst also 






Despite reductions in cardiovascular disease (CVD) morbidity and mortality in high-income countries, the 
most socioeconomically deprived groups have the highest risk of disease (1). There is evidence that 
education is a causal risk factor for CVD (2).  
Previous studies have assessed the association of socioeconomic position (SEP) with primary and 
secondary treatment rates for statins with mixed results (3-8). Lower education is associated with higher 
levels of cardiovascular risk factors (2) and therefore a greater underlying cardiovascular risk and clinical 
need for statins. However, educational differences in health-seeking behaviours or interactions between 
patients and clinicians, may mean higher educated patients are more likely to be prescribed statin 
medication (9). Independent of SEP, an over-use of statins in patients at low cardiovascular risk and 
under-use of statins in patients at high cardiovascular risk has been reported (8, 10).  
Using UK Biobank, we investigated whether for a unit increase in  QRISK3 cardiovascular risk score (11), 
participants with lower education were less likely to report taking statins for primary prevention than 
those with higher education. At the time of data collection (2006-2010) guidelines recommended 
prescribing statins to individuals with a ≥20% risk of experiencing an adverse cardiac event in 10 years, 
calculated using the Framingham risk score (12). In England and Wales, these guidelines have been 
updated to recommend prescribing based on a QRISK3 score of ≥10% (13). Cardiovascular risk 
assessments are typically carried out by a primary healthcare professional during routine health checks . 





At baseline, UK Biobank recruited 503 317 UK adults, aged 37 to 73 years, from 2006-2010. Participants 
attended assessment centres involving questionnaires, interviews, anthropometric and physical 
measurements (14). This analysis uses data from baseline assessments, linked hospital inpatient records 
and mortality statistics and linked primary care data (including prescriptions). Ethical approval for this 
study was sought from UK Biobank (project 10953). 
QRISK score 
Cardiovascular risk was assessed using the publicly available QRISK3 algorithm (see 
https://qrisk.org/three/index.php) (11). QRISK3 scores were derived for all participants with complete 
data on education, self-reported statin use and with no prevalent CVD (see exclusion criteria) (N= 472 
097) (Figure 1). Multiple imputation was used for missing data in the QRISK3 variables (see statistical 
analysis section).  
See Supplementary Methods and Supplementary Table 1 for full details of all QRISK3 variables and 
Supplementary Tables 2 and 3 for UK Biobank treatment codes, ICD-9 and ICD-10 codes used to define 
diagnoses . 
In a subset of individuals with linked primary care data, QRISK (read 2 code: 38DF.) (N=1 495), and 
QRISK2 scores (read 2 code: 39DP.) (N = 10 633) were recorded from 2007 onwards. In sensitivity 
analyses, the first recorded QRISK score was used. 
Measuring education 
Self-reported highest qualification was converted to the International Standard Classification for 
Education (ISCED) for years of education (Supplementary Table 4).  
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Measuring statin use 
Regularly prescribed medication was reported to study nurses, which was used define i) statin use and ii) 
type of statin used (Atorvastatin, Simvastatin, Fluvastatin, Pravastatin and Rosuvastatin). 
In individuals with primary care data, self-report statin use was validated by a statin prescription both 3 
months before and 3 months after baseline. In sensitivity analyses using primary care QRISK scores, 
statin use was defined as any statin prescription after a QRISK score was recorded, excluding individuals 
who reported using statins at baseline. 
Exclusion criteria 
Individuals were excluded if they had at least one diagnosis of myocardial infarction, angina, stroke, 
transient ischaemic attack, peripheral arterial disease, type 1 diabetes, chronic kidney disease or familial 
hypercholesterolaemia at baseline, as NICE guidelines state these diagnoses should result in a statin 
prescription (13), defined using ICD codes in hospital inpatient data (Supplementary Table 3). 
Complete case analyses were carried out on 368 721 individuals, with complete data on age, sex, 
education, self-reported statin use and all QRISK3 variables (Supplementary Table 1 and Figure 1).  
Code and data availability 
The derived variables have been returned to UK Biobank. The code used to derive QRISK3 scores, and 
conduct analyses is available at github.com/alicerosecarter/statin_inequalities. All analyses were carried 
out in Stata version 16.1 (StataCorp, College Station, Texas 77845 USA).   
Statistical analyses 
To maximise power and potentially reduce bias, multivariable multiple imputation by chained equations 
(15) was used to impute missing data in QRISK3 variables, assuming missing at random. The imputation 
sample was defined as all individuals with complete data on education and reported statin use. The 
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proportion of missing data for each variable ranged from 0% to 15% (Supplementary Table 5). 
Imputation was carried out within strata of education and sex to preserve interactions (16). A total of 25 
imputed datasets were generated (17), each analysed individually with results combined according to 
Rubin’s rules.  
Because the QRISK3 score is derived sex-stratified, analyses were carried out sex stratified (11).  
To confirm the validity of the derived QRISK3 score, a univariable logistic regression model was used to 
assess the association between QRISK3 score and i) statin use (as defined previously) and ii) incident 
CVD (see Supplementary Methods).  
We estimated the association between years of education with i) QRISK3 score (using linear regression) 
and ii) statin use (using logistic regression).  
Testing for interaction between QRISK3 score and education on statin use 
Logistic regression was used to estimate the association of QRISK3 score with statin use, stratified by 
years of education, estimating multiplicative interactions (sFigure 2, Route 1). Analyses were adjusted 
for date of assessment to account for changes in statin prescribing guidelines during the recruitment 
period. No other covariates were adjusted for, assuming all relevant variables are incorporated into the 
QRISK3 score. Evidence of an interaction between QRISK3 score and years of education was evaluated in 
a linear model where the interaction term QRISK3×education was included. 
Secondary analyses 
Atorvastatin has greater efficacy than Simvastatin but is more costly (18). To test whether educational 
inequalities are present in the statin type prescribed, we estimated the interaction between 
QRISK3×education with Atorvastatin compared with Simvastatin in statin users (sFigure 1 Route 2). 
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Analyses between QRISK3×education on statin use and type of statin were replicated using complete 
case data (sFigure 1, Route 3 and 4).  
Analyses were replicated in participants with linked primary care data using i) baseline measures of 
QRISK3 and self-report statin use (sFigure 1, Route 5) ii) baseline measures of QRISK3 with validated 
statin use (sFigure 1, Route 6) and iii) QRISK or QRISK2 score recorded in primary care data with statin 
prescriptions (sFigure 1, Route 7). Primary care QRISK scores were included if they were recorded on or 
prior to the date of first statin prescription, but time between both events was not accounted for. 
Sensitivity analyses were carried out excluding participants who reported taking non-statin lipid-
lowering therapies. Main analyses were also replicated on the additive scale for interaction. 
Two further QRISK3 scores were derived using baseline data excluding i) systolic blood pressure 
variability and ii) family history of CVD from QRISK3 scores (see supplementary methods). The pairwise 
correlation between scores with and without these variables was tested. 
Results 
UK Biobank sample 
In primary analyses (N = 472 097) 55% of participants were female with a mean age of 56. In females, 
the QRISK3 score implied a mean 10-year risk of a cardiovascular event of 6.9% (standard deviation (SD) 
= 5.5). In males, the QRISK3 score implied mean a 10-year risk of a cardiovascular event of 13.1% (SD = 
8.4). Participants were more likely to have completed ≥20 years of education (female = 35%, male = 
38%) than ≤7 years of education (female = 14%, male = 14%). 10% of females and 17% of males reported 
using statins (Supplementary Table 6). 
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The distribution of variables was similar between the multiply imputed data, complete case data, and 
the subset of participants with primary care data (Supplementary Table 6).  
Association of QRISK3 score with statins and cardiovascular disease  
Per one unit increase in QRISK3 score (i.e., a 1% increase in the 10-year risk of experiencing a 
cardiovascular event) in females, the odds ratio (OR) for statin use was 1.12 (95% confidence interval 
[CI]: 1.12 to 1.13) and the OR for incident CVD was 1.14 (95% CI: 1.14 to 1.15) (Figure 2, Supplementary 
Figure 2 and Supplementary Table 7). Females with a QRISK3 score of ≥10 were 1.34 times (95% CI: 1.31 
to 1.36) more likely to report using statins than those with a QRISK score <10. In males, the OR for statin 
use was 1.07 (95% CI: 1.07 to 1.07) and 1.09 (95% CI: 1.09 to 1.09) for incident CVD per unit higher 
QRISK3 score (Figure 2, Supplementary Figure 2 and Supplementary Table 7). Males with a QRISK3 score 
of ≥10 were 1.49 times (95% CI: 1.46 to 1.52) more likely to report using statins than those with a QRISK 
score <10. Participants reporting using statins had lower mean low-density lipoprotein cholesterol levels 
(the biological target of statins), compared with non-statin users (Supplementary Figure 3). 
Association of education with QRISK3 score and statin use 
Per year increase in education was associated with a -0.30 (95% CI: -0.30 to -0.29) reduction in mean 
QRISK3 score in females and a -0.35 (95% CI: -0.35 to -0.34) reduction in males (Supplementary Table 8 
and Supplementary Figure 4).  
Statin prevalence was highest in those with ≤7 years of education (equivalent to no formal 
qualifications) across all strata of cardiovascular risk (Supplementary Figure 5 and Supplementary Table 
9). Each additional year of education was associated with a lower odds of statin use (OR in females: 
0.93; 95% CI: 0.93 to 0.93; OR in males: 0.96; 95% CI: 0.96 to 0.96) (Supplementary Figure 6).  
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Interaction between education and QRISK3 score in relation to statin use 
There was evidence of an interaction between QRISK3×education on statin use. In females, per unit 
increase in QRISK3, the OR for reporting statin use in those with ≥20 years (equivalent to obtaining a 
degree) was 1.14 (95% CI: 1.14 to 1.15) compared with an OR of 1.07 (95% CI: 1.07 to 1.07) for those 
with ≤7 years of education (Figure 1). In males, the OR for statin use per unit increase in QRISK3 score in 
those with ≥20 years of education was 1.08 (95% CI: 1.08 to 1.08) compared with an OR of 1.04 (95% CI: 
1.04 to 1.05) for those with ≤7 years (Figure 2).  
Secondary analyses 
There was little evidence of an interaction between QRISK3×education on statin type (Supplementary 
Table 10 and Supplementary Figure 7).  
In analyses in participants with primary care data using i) baseline measures of QRISK3 and self-report 
statin use, ii) baseline measures of QRISK3 with prescription-validated statin use and iii) QRISK or QRISK2 
score recorded in primary care data with a statin prescription, similar interactions were observed to the 
main results, although evidence of an interaction was weaker in the primary care QRISK analyses in 
males (Figure 3 and Supplementary Figure 8).  
Sensitivity analyses i) using complete case data and ii) excluding participants on non-statin lowering 
therapy were consistent with the main results (Supplementary Tables 11 and 12).There was evidence of 
an additive interaction between QRISK3×education , although the strength of the interaction was 
weaker compared with the multiplicative scale (Supplementary Figure 9). 
Pairwise correlation between the baseline derived QRISK3 score and QRISK3 scores derived excluding i) 
systolic blood pressure variability estimated from the difference between two baseline measures and ii) 




Despite a higher prevalence of statin use in less educated participants, these participants were less likely 
to receive statin treatment compared to more highly educated individuals given an equivalent increase 
in QRISK3 cardiovascular risk score. 
Results in context 
Cardiovascular risk factors partly mediate the association between education and CVD (2, 19-21) and 
likely contribute to the greater clinical need for statins in lower educated individuals. However, 
differences in cardiovascular preventative medication may be further contributing to socioeconomic 
inequalities. We found the prevalence of statin use in participants at low cardiovascular risk (QRISK3 
score of <10%) was similar to previous analyses in UK primary care databases (10). However, notably 
here, we found the prevalence of statin use in participants with low cardiovascular risk (<10% QRISK3) 
was higher in participants with lower educational attainment compared with higher educational 
attainment. 
Since 2009, National Health Service (NHS) health checks have been offered to English and Welsh 
residents aged 40-74 without pre-existing conditions every 5 years, aiming to prevent a number of 
diseases including CVD (22). A recent systematic review identified seven studies illustrating inequalities 
in favour of those with higher SEP attending preventative health checks (23), including a trend towards 
lower uptake in smokers; a socially patterned cardiovascular risk factor (23, 24). Increased engagement 
with preventative screening may reduce inequalities in CVD and statins. However, in analyses using 
QRISK scores and statin prescriptions recorded in primary care data, these inequalities remained. 
Therefore, health-seeking behaviours, including attending primary care clinics, cannot be the sole driver 
of inequalities.  
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Previous studies found mixed evidence for the association between SEP and statin use, including the 
direction of effect (3-8). However, there was often limited consideration for underlying cardiovascular 
risk (3-6). Forde and colleagues adjusted for Framingham risk score to control for cardiovascular risk (7). 
In contrast to our results, they found no evidence of inequalities in statin use by strata of employment 
grade in the Whitehall II study. This difference could be due to different measures of SEP (education vs 
employment) or cohort differences, where the Whitehall II study is an occupational cohort. The QRISK 
score has also been shown to have a greater predictive power than the Framingham risk score (25). 
Therefore, our analyses may better account for cardiovascular risk.  
In participants with primary care data, a large number of participants reported taking statins to study 
nurses but had no prescription at baseline. These Individuals are potentially a combination of those 
purchasing statins over the counter, having a private prescription, or no longer being prescribed statins. 
Most individuals (91%) without a linked prescription reported taking Simvastatin (the only statin 
available over the counter). It is possible that accessing statins through private practices or over the 
counter are further contributing to inequalities in cardiovascular outcomes.  
Strengths and limitations 
The major strength of our work is the large sample size and array of data available. Given the age of 
participants, statin prevalence is high. Using linked primary care data for 44% of the eligible sample we 
could i) validate self-reported statin use and ii) compare different mechanisms inequalities may arise. 
Where inequalities are present in primary care QRISK scores, inequalities are potentially due to factors 
within clinic settings. Using QRISK3 scores derived at baseline, inequalities may be due to differences in 
health seeking behaviour. 
Lifestyle and behavioural characteristics included in the QRISK3 score are likely measured more 
accurately in UK Biobank compared clinics. However, not all variables, or repeat measurements of 
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variables specified in the QRISK3 algorithm are available in UK Biobank (11). The QRISK3 algorithm 
includes medications where an individual has two or more prescriptions for each class of medication 
(e.g., corticosteroid or atypical antipsychotic). We relied on a single self-report measure at baseline, 
which may overestimate medication use. However, the magnitude to which these measurements differ 
is unlikely to introduce much bias to the QRISK3 score. Systolic blood pressure variability and coronary 
heart disease in a first degree relative under the age of 60, are not available in UK Biobank. Although we 
have included measures likely to capture some of these variables, this may introduce bias to the QRISK3 
estimate. 
Participants in UK Biobank are generally of a higher SEP and healthier than the general population, 
where higher education has been shown to increase participation and socially patterned cardiovascular 
risk factors including smoking decrease participation (14, 27). Additionally, participants with lower SEP 
may differ to those of an equivalent SEP (or level of educational attainment) in the general population. 
Therefore, inequalities in the wider population may be greater than those reported here.  
In these data it is not possible to identify who has both received a prescription and subsequently had the 
prescription filled. E.g., in primary analyses, individuals with the lowest levels of educational attainment 
may have received a prescription for a statin, but not collected the medication. This may explain why 
the interaction between QRISK3 scores, and educational attainment is larger in the analyses using self-
report statin use compared with statin prescriptions in primary care data.  
We have used the ISCED definitions of education as a measure of SEP. Although education is a strong 
predictor of adulthood SEP, correlating with future employment and income, adult SEP may explain 




Our results indicate two potential mechanisms for these inequalities. Firstly, there are likely to be 
differences in health seeking behaviour (29). Secondly, there are important interactions between the 
healthcare practitioner and patient resulting in unequal prescribing of statins.  
Given persisting inequalities in CVD, addressing the contribution of inequalities in statin prescribing 
provides a clear policy target. However, this requires systemic change and different interventions may 
be required to address the different mechanisms of inequalities. Future research should investigate the 
what factors are driving inequalities, such as patient preference for treatment (30) or non up-take of 
preventative health checks. 
Conclusions  
Our analyses demonstrate that for a unit increase in cardiovascular risk, individuals with lower levels of 
education are less likely to be prescribed statins compared with higher educated individuals, meaning 
differences in statin prescribing likely contribute to inequalities in cardiovascular disease. Policies should 
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Figure 1: Study flow chart identifying eligible participants for analysis 
Figure 2: Odd ratio for self-report statin use per unit increase in baseline QRISK3 score with no 
education interaction and stratified by years of education in females and males, adjusted for date of 
baseline assessment centre 
Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale. P 
value for interaction in females = 1.896x10-85 and males = 1.999x10-48 
Figure 3:  Odd ratio for statin use recorded in primary care prescription data per unit increase in A) 
baseline QRISK3 score and B) QRISK or QRISK2 score recorded in primary care, in females and males 
adjusted for date of baseline assessment centre or date of QRISK assessment in primary care 
Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale. 
Baseline QRISK3: P value for interaction in females =5.476 x10-10 and males = 4.046x10-7 
QRISK score recorded in primary care: P value for interaction in females = 0.006 and males = 0.413  
